Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,311

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Open access
Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A.R., Wick, W., Kostine, M., Peters, S., Jordan, K., Larkin, J.·2022·Annals of Oncology
DOI 10.1016/j.annonc.2022.10.001
Open this paper in CoChat — free account

Abstract

OverviewAdverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs).irAEs are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Supplementary Table S1, available at https://doi.org/10. 1016/j.annonc.2022.10.001). 1 The aim of this European Society for Medical Oncology (ESMO) Clinical Practice Guideline (CPG) is to provide specific guidance on irAE management.Recommendations provided are based on evidence from the scientific literature, clinical experience and analogy to the treatment of autoimmune diseases (ADs), where appropriate.Consensus for the recommendations was obtained by direct communication, scientific debate and agreement.Further information regarding the provision of patient information, routine baseline screening before ICI initiation, monitoring during ICI therapy, management of outpatients versus inpatients and that of corticosteroid (CS)-refractory patients and patients with specific conditions can be found in Section 1 of the Supplementary Material, available at https://doi.org/10.1016/j.annonc.2022.10.001. General guidance for immunosuppressionirAE management generally consists of four sequential steps: (i) diagnosis and grading of irAEs, (ii) ruling out differential diagnoses and pre-immunosuppression work-up, (iii) selecting the appropriate immunosuppression strategy for grade !2 events and (iv) active evaluation at 72 h to adapt treatment.See Supplementary Table S2 and Section 1 of the Supplementary Material, available at https://doi.org/ 10.1016/j.annonc.2022.10.001.To minimise the occurrence of CS-induced AEs, the following general guidance is proposed 2 :The lowest effective CS dose should be prescribed for the shortest possible duration, which, in general will be several weeks for grade !3 irAEs, including tapering CS therapy tapering or discontinuation only on medical advice Lifestyle adaptations to minimise the risk of CS-induced AEs Immunosuppressive drugsOptimising the choice of immunosuppressive agents.Prospective studies evaluating the safety and efficacy of immunosuppressant agents in irAE management are

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2022.10.001

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 107 references

Cited by

See all 1,311

Metadata

Authors
Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., Jordan, K., & Larkin, J.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2022-12
Volume
33
Issue
12
Pages
1217-1238
ISSN
0923-7534 (ISSN-L)
DOI
10.1016/j.annonc.2022.10.001
OpenAlex
W4306692674
Cited by
1,311
References
107
FWCI
82.11
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. https://app.cochat.ai/papers/10.1016/j.annonc.2022.10.001
The paper
Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., Jordan, K., & Larkin, J. (2022). Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. https://doi.org/10.1016/j.annonc.2022.10.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.